Targeting the TGFβ Pathway With Galunisertib, a TGFβRI SMI, Promotes Anti-Tumor Immunity Leading to Durable, Complete Responses, as Monotherapy and in Combination With Checkpoint Inhibition
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p402
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2015
Authors
Publisher
BMJ